Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease

Jae Myeong Kang; Sang Yoon Lee; Seongho Seo; Hye Jin Jeong; Sung Ho Woo; Hyon Lee; Yeong Bae Lee; Byeong Kil Yeon; Dong Hoon Shin; Kee Hyung Park; Hyejin Kang; Nobuyuki Okamura; Shozo Furumoto; Kazuhiko Yanai; Victor L. Villemagne; Joon Kyung Seong; Duk L. Na; Tatsuo Ido; Jaelim Cho; Kyoung Min Lee; Young Noh

doi:10.1016/j.neurobiolaging.2017.08.008

Tau positron emission tomography using [¹⁸F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease

Jae Myeong Kang, Sang Yoon Lee, Seongho Seo, Hye Jin Jeong, Sung Ho Woo, Hyon Lee, Yeong Bae Lee, Byeong Kil Yeon, Dong Hoon Shin, Kee Hyung Park, Hyejin Kang, Nobuyuki Okamura, Shozo Furumoto, Kazuhiko Yanai, Victor L. Villemagne, Joon Kyung Seong, Duk L. Na, Tatsuo Ido, Jaelim Cho, Kyoung Min LeeYoung Noh

Department of Artificial Intelligence

Research output: Contribution to journal › Article › peer-review

42 Citations (Scopus)

Abstract

This study aims to evaluate the clinical validity of [¹⁸F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [¹⁸F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [¹⁸F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [¹⁸F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [¹⁸F]THK5351 and [¹⁸F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [¹⁸F]THK5351 retention and glucose hypometabolism in [¹⁸F] fluorodeoxyglucose were noticeable in the focal variants of AD. [¹⁸F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [¹⁸F]THK5351 is reflective of tau-related AD pathology.

Original language	English
Pages (from-to)	210-219
Number of pages	10
Journal	Neurobiology of Aging
Volume	59
DOIs	https://doi.org/10.1016/j.neurobiolaging.2017.08.008
Publication status	Published - 2017 Nov

Keywords

Alzheimer's disease
Neurofibrillary tangles
Positron emission tomography
THK
Tau

ASJC Scopus subject areas

Neuroscience(all)
Ageing
Developmental Biology
Clinical Neurology
Geriatrics and Gerontology

Access to Document

10.1016/j.neurobiolaging.2017.08.008

Cite this

Kang, J. M., Lee, S. Y., Seo, S., Jeong, H. J., Woo, S. H., Lee, H., Lee, Y. B., Yeon, B. K., Shin, D. H., Park, K. H., Kang, H., Okamura, N., Furumoto, S., Yanai, K., Villemagne, V. L., Seong, J. K., Na, D. L., Ido, T., Cho, J., ... Noh, Y. (2017). Tau positron emission tomography using [¹⁸F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiology of Aging, 59, 210-219. https://doi.org/10.1016/j.neurobiolaging.2017.08.008

Kang, JM, Lee, SY, Seo, S, Jeong, HJ, Woo, SH, Lee, H, Lee, YB, Yeon, BK, Shin, DH, Park, KH, Kang, H, Okamura, N, Furumoto, S, Yanai, K, Villemagne, VL, Seong, JK, Na, DL, Ido, T, Cho, J, Lee, KM & Noh, Y 2017, 'Tau positron emission tomography using [¹⁸F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease', Neurobiology of Aging, vol. 59, pp. 210-219. https://doi.org/10.1016/j.neurobiolaging.2017.08.008

@article{7046e073d8984fe48cc03ba7bc818d05,

title = "Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease",

abstract = "This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.",

keywords = "Alzheimer's disease, Neurofibrillary tangles, Positron emission tomography, THK, Tau",

author = "Kang, {Jae Myeong} and Lee, {Sang Yoon} and Seongho Seo and Jeong, {Hye Jin} and Woo, {Sung Ho} and Hyon Lee and Lee, {Yeong Bae} and Yeon, {Byeong Kil} and Shin, {Dong Hoon} and Park, {Kee Hyung} and Hyejin Kang and Nobuyuki Okamura and Shozo Furumoto and Kazuhiko Yanai and Villemagne, {Victor L.} and Seong, {Joon Kyung} and Na, {Duk L.} and Tatsuo Ido and Jaelim Cho and Lee, {Kyoung Min} and Young Noh",

note = "Funding Information: This study was supported by a grant from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare of the Republic of Korea (grant No: HI14C1135). Publisher Copyright: {\textcopyright} 2017 Elsevier Inc.",

year = "2017",

month = nov,

doi = "10.1016/j.neurobiolaging.2017.08.008",

language = "English",

volume = "59",

pages = "210--219",

journal = "Neurobiology of Aging",

issn = "0197-4580",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease

AU - Kang, Jae Myeong

AU - Lee, Sang Yoon

AU - Seo, Seongho

AU - Jeong, Hye Jin

AU - Woo, Sung Ho

AU - Lee, Hyon

AU - Lee, Yeong Bae

AU - Yeon, Byeong Kil

AU - Shin, Dong Hoon

AU - Park, Kee Hyung

AU - Kang, Hyejin

AU - Okamura, Nobuyuki

AU - Furumoto, Shozo

AU - Yanai, Kazuhiko

AU - Villemagne, Victor L.

AU - Seong, Joon Kyung

AU - Na, Duk L.

AU - Ido, Tatsuo

AU - Cho, Jaelim

AU - Lee, Kyoung Min

AU - Noh, Young

N1 - Funding Information: This study was supported by a grant from the Korea Healthcare Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare of the Republic of Korea (grant No: HI14C1135). Publisher Copyright: © 2017 Elsevier Inc.

PY - 2017/11

Y1 - 2017/11

N2 - This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.

AB - This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.

KW - Alzheimer's disease

KW - Neurofibrillary tangles

KW - Positron emission tomography

KW - THK

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85029616089&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2017.08.008

DO - 10.1016/j.neurobiolaging.2017.08.008

M3 - Article

C2 - 28890300

AN - SCOPUS:85029616089

SN - 0197-4580

VL - 59

SP - 210

EP - 219

JO - Neurobiology of Aging

JF - Neurobiology of Aging

ER -